Company Description
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.
The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.
It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019.
Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc is a subsidiary of Mayne Pharma Ventures Pty Ltd.
| Country | United States |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Francis E. O'Donnell Jr., M.D. |
Contact Details
Address: 4830 W. Kennedy Blvd., Suite 600 Tampa, Florida 33609 United States | |
| Phone | (813) 766-2462 |
| Website | inhibitortx.com |
Stock Details
| Ticker Symbol | INTI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001042418 |
| CUSIP Number | 45720M105 |
| ISIN Number | US45720M1053 |
| Employer ID | 54-1641133 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Francis E. O'Donnell Jr., M.D. | Founder, Executive Chairman and Chief Executive Officer |
| James A. McNulty CPA | Interim Chief Financial Officer, Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 10-Q | Quarterly Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Dec 14, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Oct 18, 2023 | 8-K | Current Report |
| Aug 29, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |
| May 31, 2023 | 8-K | Current Report |
| May 23, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| May 23, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |